Leticia Corrales
Laboratory Head Boehringer Ingelheim
Leticia Corrales is a Principal Scientist at Boehringer Ingelheim with expertise in the non clinical pharmacology of T cell engagers (TcEs). Her work encompasses target identification, the design and interpretation of proof of concept assays, and the advancement of a broad TcE portfolio. She contributes mechanistic insight that informs translational strategies for next generation immunotherapies. With a strong background in tumour immunology, she integrates biological understanding with experimental strategy to support the development of effective TcE therapeutics.
Seminars
Wednesday 10th June 2026
T‑Cell Redirecting Therapies: Delivering Deeper & Broader Clinical Impact
12:30 pm
- Exploring how T‑cell engagers (TcEs) are a powerful next-generation immunotherapy that reprogram “cold” tumors into “hot” tumors by redirecting T-cells toward tumor antigens
- Discussing how Boehringer Ingelheim is advancing a diverse and innovative TcE pipeline, which includes assets such as obrixtamig (DLL3/CD3), supported by cutting-edge antigen discovery platforms to identify tumor-selective targets and expand therapeutic opportunities
- Overcoming solid tumor challenges with integrated strategies that include identifying tumor-specific targets, engineering selective and potent TcE formats, applying smart combinations, and selecting the right patients to maximize clinical benefit and therapeutic window
